Cantor Fitzgerald Forecasts PLRX FY2025 Earnings

Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Pliant Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings per share of ($1.51) for the year. Cantor Fitzgerald currently has a "Neutral" rating on the stock. The consensus estimate for Pliant Therapeutics' current full-year earnings is ($3.64) per share.

Other equities research analysts also recently issued reports about the company. Oppenheimer reiterated a "market perform" rating on shares of Pliant Therapeutics in a report on Monday, February 10th. Leerink Partners downgraded shares of Pliant Therapeutics from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $33.00 to $2.00 in a research report on Monday, March 3rd. Leerink Partnrs cut shares of Pliant Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, March 3rd. Needham & Company LLC reiterated a "hold" rating and set a $10.00 price objective on shares of Pliant Therapeutics in a report on Tuesday, March 4th. Finally, HC Wainwright reissued a "neutral" rating on shares of Pliant Therapeutics in a research report on Tuesday, March 4th. Twelve investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $13.31.

Remove Ads

Pliant Therapeutics Trading Down 11.7 %

Pliant Therapeutics stock traded down $0.19 during trading hours on Thursday, reaching $1.43. 2,090,416 shares of the company's stock were exchanged, compared to its average volume of 856,056. Pliant Therapeutics has a twelve month low of $1.26 and a twelve month high of $16.52. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. The firm's 50 day simple moving average is $8.11 and its 200 day simple moving average is $11.47. The firm has a market capitalization of $87.57 million, a PE ratio of -0.43 and a beta of 1.18.

Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.99) by $0.17.

Institutional Trading of Pliant Therapeutics

A number of hedge funds have recently bought and sold shares of PLRX. China Universal Asset Management Co. Ltd. increased its position in shares of Pliant Therapeutics by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,903 shares of the company's stock valued at $170,000 after purchasing an additional 1,209 shares during the last quarter. Swiss National Bank increased its holdings in Pliant Therapeutics by 1.6% during the fourth quarter. Swiss National Bank now owns 95,700 shares of the company's stock worth $1,260,000 after buying an additional 1,500 shares during the last quarter. Atria Investments Inc raised its position in Pliant Therapeutics by 18.1% in the fourth quarter. Atria Investments Inc now owns 11,821 shares of the company's stock worth $156,000 after acquiring an additional 1,812 shares during the period. R Squared Ltd purchased a new position in Pliant Therapeutics in the fourth quarter valued at about $33,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in Pliant Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 459,384 shares of the company's stock valued at $6,050,000 after acquiring an additional 2,721 shares during the last quarter. 97.30% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CEO Bernard Coulie sold 52,419 shares of the stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $11.20, for a total value of $587,092.80. Following the completion of the sale, the chief executive officer now owns 430,517 shares in the company, valued at $4,821,790.40. This represents a 10.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Hans Hull sold 15,936 shares of the firm's stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $11.20, for a total transaction of $178,483.20. Following the transaction, the insider now directly owns 211,558 shares in the company, valued at $2,369,449.60. The trade was a 7.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 91,855 shares of company stock worth $1,026,628. 6.40% of the stock is owned by corporate insiders.

About Pliant Therapeutics

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.